Journal article
Authors list: Metzger, Monika L.; Mauz-Koerholz, Christine
Publication year: 2019
Pages: 1142-1157
Journal: British Journal of Haematology
Volume number: 185
Issue number: 6
ISSN: 0007-1048
eISSN: 1365-2141
Open access status: Bronze
DOI Link: https://doi.org/10.1111/bjh.15789
Publisher: Wiley
Abstract:
The epidemiology, outcome and targeted immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma were discussed during the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma September 26th-29th 2018 in Rotterdam, the Netherlands. This review summarizes some of those presentations, as well as other current and novel antibody therapy, immune check-point inhibitors, chimeric antigen receptor T cells, cancer vaccines and cytotoxic T lymphocyte therapy.
Citation Styles
Harvard Citation style: Metzger, M. and Mauz-Koerholz, C. (2019) Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma, British Journal of Haematology, 185(6), pp. 1142-1157. https://doi.org/10.1111/bjh.15789
APA Citation style: Metzger, M., & Mauz-Koerholz, C. (2019). Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. British Journal of Haematology. 185(6), 1142-1157. https://doi.org/10.1111/bjh.15789
Keywords
ACUTE-LYMPHOBLASTIC-LEUKEMIA; antibody therapy; B-CELL LYMPHOMA; BRENTUXIMAB VEDOTIN; cellular immunotherapy; chimeric antigen receptor; cytokine release syndrome; CYTOTOXIC T-LYMPHOCYTES; DOSE-ADJUSTED EPOCH; Hodgkin lymphoma; non-Hodgkin lymphoma; OPEN-LABEL; PEDIATRIC-PATIENTS; PHASE-II; RITUXIMAB THERAPY; vaccine therapy
